FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3140555419> ?p ?o ?g. }

• W3140555419 endingPage "4333" @default.
• W3140555419 startingPage "4323" @default.
• W3140555419 abstract "To evaluate pharmacokinetic equivalence and preliminary safety of the adalimumab biosimilar CT-P17 administered via autoinjector (CT-P17 AI) or prefilled syringe (CT-P17 PFS) in healthy subjects.This phase I, open-label study (ClinicalTrials.gov: NCT04295356) randomised subjects (1:1) to receive a single 40-mg (100 mg/mL) dose of CT-P17 AI or CT-P17 PFS. Primary endpoint was pharmacokinetic equivalence of CT-P17 AI to CT-P17 PFS for: area under the concentration-time curve from time zero to infinity (AUC0-inf ); area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-last ); maximum serum concentration (Cmax ). Equivalence was determined if the 90% confidence interval for the geometric least-squares mean ratio was within the 80-125% equivalence margin. Additional pharmacokinetic endpoints, safety and immunogenicity were evaluated.Of 193 subjects who were randomised (98 CT-P17 AI; 95 CT-P17 PFS), 180 received study drug. Pharmacokinetic equivalence was demonstrated: 90% confidence intervals were within the 80-125% equivalence margin (AUC0-inf : 93.98-114.29; AUC0-last : 91.09-121.86; Cmax : 94.08-111.90). Mean serum CT-P17 concentrations, secondary pharmacokinetic parameters and numbers of subjects with antidrug antibodies (ADAs) or neutralising ADAs were comparable between groups. AUC0-inf , AUC0-last and Cmax were numerically lower for ADA-positive than for ADA-negative subjects (both groups); pharmacokinetic equivalence was also demonstrated among ADA-positive subjects. CT-P17 AI and CT-P17 PFS were well tolerated, with comparable overall safety profiles.CT-P17 AI and CT-P17 PFS were pharmacokinetically equivalent. Overall safety and immunogenicity were comparable between the 2 delivery devices." @default.
• W3140555419 created "2021-04-13" @default.
• W3140555419 creator A5028063859 @default.
• W3140555419 creator A5028185603 @default.
• W3140555419 creator A5059206584 @default.
• W3140555419 creator A5062224388 @default.
• W3140555419 creator A5066408904 @default.
• W3140555419 creator A5080646462 @default.
• W3140555419 creator A5082933795 @default.
• W3140555419 creator A5085664798 @default.
• W3140555419 creator A5087617559 @default.
• W3140555419 date "2021-05-09" @default.
• W3140555419 modified "2023-10-01" @default.
• W3140555419 title "Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT‐P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjects" @default.
• W3140555419 cites W1602142879 @default.
• W3140555419 cites W1965596045 @default.
• W3140555419 cites W1967295501 @default.
• W3140555419 cites W2017244185 @default.
• W3140555419 cites W2017331060 @default.
• W3140555419 cites W2064688760 @default.
• W3140555419 cites W2120393706 @default.
• W3140555419 cites W2142004396 @default.
• W3140555419 cites W2185272193 @default.
• W3140555419 cites W2480028188 @default.
• W3140555419 cites W2513381414 @default.
• W3140555419 cites W2547405693 @default.
• W3140555419 cites W2731060601 @default.
• W3140555419 cites W2795999530 @default.
• W3140555419 cites W2804599232 @default.
• W3140555419 cites W2809785191 @default.
• W3140555419 cites W2899068765 @default.
• W3140555419 cites W2904268507 @default.
• W3140555419 cites W2905086954 @default.
• W3140555419 cites W2912423540 @default.
• W3140555419 cites W2916175354 @default.
• W3140555419 cites W2946738061 @default.
• W3140555419 cites W2953191080 @default.
• W3140555419 cites W2966643887 @default.
• W3140555419 cites W2972094986 @default.
• W3140555419 cites W2997974446 @default.
• W3140555419 cites W3013248954 @default.
• W3140555419 cites W3101734241 @default.
• W3140555419 cites W3109122041 @default.
• W3140555419 cites W3124773781 @default.
• W3140555419 cites W3127478789 @default.
• W3140555419 doi "https://doi.org/10.1111/bcp.14850" @default.
• W3140555419 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8597139" @default.
• W3140555419 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33822406" @default.
• W3140555419 hasPublicationYear "2021" @default.
• W3140555419 type Work @default.
• W3140555419 sameAs 3140555419 @default.
• W3140555419 citedByCount "5" @default.
• W3140555419 countsByYear W31405554192021 @default.
• W3140555419 countsByYear W31405554192022 @default.
• W3140555419 countsByYear W31405554192023 @default.
• W3140555419 crossrefType "journal-article" @default.
• W3140555419 hasAuthorship W3140555419A5028063859 @default.
• W3140555419 hasAuthorship W3140555419A5028185603 @default.
• W3140555419 hasAuthorship W3140555419A5059206584 @default.
• W3140555419 hasAuthorship W3140555419A5062224388 @default.
• W3140555419 hasAuthorship W3140555419A5066408904 @default.
• W3140555419 hasAuthorship W3140555419A5080646462 @default.
• W3140555419 hasAuthorship W3140555419A5082933795 @default.
• W3140555419 hasAuthorship W3140555419A5085664798 @default.
• W3140555419 hasAuthorship W3140555419A5087617559 @default.
• W3140555419 hasBestOaLocation W31405554191 @default.
• W3140555419 hasConcept C112705442 @default.
• W3140555419 hasConcept C126322002 @default.
• W3140555419 hasConcept C203092338 @default.
• W3140555419 hasConcept C22979827 @default.
• W3140555419 hasConcept C2989005 @default.
• W3140555419 hasConcept C42404028 @default.
• W3140555419 hasConcept C44249647 @default.
• W3140555419 hasConcept C535046627 @default.
• W3140555419 hasConcept C59491497 @default.
• W3140555419 hasConcept C71924100 @default.
• W3140555419 hasConcept C98274493 @default.
• W3140555419 hasConceptScore W3140555419C112705442 @default.
• W3140555419 hasConceptScore W3140555419C126322002 @default.
• W3140555419 hasConceptScore W3140555419C203092338 @default.
• W3140555419 hasConceptScore W3140555419C22979827 @default.
• W3140555419 hasConceptScore W3140555419C2989005 @default.
• W3140555419 hasConceptScore W3140555419C42404028 @default.
• W3140555419 hasConceptScore W3140555419C44249647 @default.
• W3140555419 hasConceptScore W3140555419C535046627 @default.
• W3140555419 hasConceptScore W3140555419C59491497 @default.
• W3140555419 hasConceptScore W3140555419C71924100 @default.
• W3140555419 hasConceptScore W3140555419C98274493 @default.
• W3140555419 hasFunder F4320318316 @default.
• W3140555419 hasIssue "11" @default.
• W3140555419 hasLocation W31405554191 @default.
• W3140555419 hasLocation W31405554192 @default.
• W3140555419 hasLocation W31405554193 @default.
• W3140555419 hasOpenAccess W3140555419 @default.
• W3140555419 hasPrimaryLocation W31405554191 @default.
• W3140555419 hasRelatedWork W1989480569 @default.
• W3140555419 hasRelatedWork W2033685750 @default.
• W3140555419 hasRelatedWork W2053536280 @default.

• next